Publication | Closed Access

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

AllergyUpadacitinib Versus PlaceboAtopic DermatitisAllergy MedicineClinical TrialsSkin AllergyClinical DermatologyDermatologyMedicineReplicate Double-blindMeasure Up 1Skin Testing